A retrospective single-center study to determine use, efficacy, and tolerability of monoclonal antibodies against calcitonin gene-related peptide or CGRP receptor in patients with migraine initiated on a mAb-CGRP
Latest Information Update: 01 Aug 2021
At a glance
- Drugs Erenumab (Primary) ; Fremanezumab (Primary) ; Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Aug 2021 New trial record
- 06 Jun 2021 Results presented at the 63rd Annual Scientific Meeting of the American Headache Society